The arthritic Paradigm
Paradigm Biopharma (ASX: PAR) listed on the ASX in August 2015. The company focuses on repurposing pentosan polysulphate sodium (PPS) and CEO Paul Rennie tells Alan Kohler Paradigm has an …
Normal CTA (3 top stocks)
Latest Posts
April 18, 2019
April 18, 2019
April 18, 2019
April 18, 2019
April 18, 2019
April 18, 2019
April 17, 2019
April 17, 2019
April 17, 2019
April 16, 2019